Companion diagnostics are very complex and expensive to develop. Our intention is to collect exploratory data to determine if bisantrene specifically effects m6A levels in patients in an exploratory add-on to the cardioprotection study, and only if it does, then start the process of developing a companion diagnostic. This is the most capital efficient approach.
We have done a lot of work identifying what approaches we could use to develop a practical diagnostic. The good news
Pillar 1 - FTO (new thread), page-2872
-
- There are more pages in this discussion • 100 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
